Organizing Committee
OCM Member
Baylor College of Medicine , USA
Biography :

Dr. Keith Syson Chan received his PhD from the University of Texas, MD Anderson Cancer Center in 2004. He was trained under the classical concept that epithelial cancers develop via a multi-step process. Through pathologic evaluation of tumor tissues, he developed the appreciation that cancer is a disease of aberrant cellular differentiation. He then joined Prof. Irving Weissman’s laboratory at Stanford University to continue his postdoctoral studies (2004-09). He was amongst the first to isolate cancer stem cells (CSCs) from human bladder urothelial carcinomas, and investigated CD47 as a mechanism for immune evasion. Dr. Chan is currently an associate professor at Baylor College of Medicine, emphasizing on translating CSC-targeted therapeutics into human clinical trials.

Research Interest :

Dr. Keith Syson Chan was amongst the first to isolate cancer stem cells (CSCs) from human bladder urothelial carcinomas, and investigated CD47 as a mechanism for immune evasion.

OCM Member
National Institutes of Health , USA
Biography :

Dr. Ming Lei is a molecular geneticist by training. He earned his PhD degree from Cornell University and continued his postdoctoral training there. He was a faculty member at the Medical College of Wisconsin, where he taught Genetics and Microbiology to medical students and graduate students. He was a NIH funded principal investigator focusing his research efforts on the regulation of eukaryotic DNA replication. He began his governmental service in 2006 at the National Science Foundation, where he managed NSF’s research grant portfolio in Molecular Biology, Genetics and Genomics. He has been with the National Cancer Institute since 2008.

OCM Member
Roswell Park Cancer Institute , USA
Biography :

Dean Tang, PhD, was trained as a Pathologist and is currently Professor & Chair in Department of Pharmacology & Therapeutics at Roswell Park Cancer Institute. His Master of Science thesis research (1986-1989), conducted in Dr. Hong-shen Tian’s laboratory in Wuhan University School of Medicine, focused on establishing lung cancer metastasis models. To continue his research on metastasis, Dr. Tang joined Dr. Ken Honn’s lab at Wayne State University (WSU) in 1989 to study the role of integrin receptors in mediating tumor cell – extracellular matrix interactions, tumor cell invasion, and tumor cell extravasation. Dr. Tang obtained his PhD in Cancer Biology in 1994 and stayed at WSU for a few years to explore apoptosis-based anti-prostate cancer therapeutics. In 1998, he was awarded a Burroughs-Wellcome Hitchings-Elion post-doctoral Fellowship to study oligodendrocyte precursor cell (OPC) development in Dr. Martin Raff’s lab in Medical Research Council (MRC) Laboratory for Molecular & Cellular Biology (LMCB) of University College London (UCL, UK). Dr. Tang returned to America in June of 2000 to join the MD Anderson Cancer Center Department of Epigenetics and Molecular Carcinogenesis till May of 2016.

Research Interest :

Dr. Tang and his colleagues have been studying cancer stem cells and cancer cell heterogeneity with a focus on prostate cancer. His career goals are to identify novel therapeutics and therapeutic combinations for personalized cancer treatment.

OCM Member
Institut de Biologie Valrose- Ibv , France
Biography :

Thierry Virolle is a Research Director (permanent position) at Institut National de la Santé et de la Recherche Médicale (INSERM), Head of the Team Cancer Stem Cell Plasticity and Functional intra-tumor Heterogeneity at the Institute of Biologie Valrose (iBV). He is Co-Founder of the French National Sud Cancer Stem Cell Network, SUNRiSE dedicated to the study of cancer stem cell.

Research Interest :

He is Doctor of Science (PhD) at Nice Sophia Antipolis University (2000), his researches focus on the regulation of the plasticity of glioblastoma cancer stem cells and its contribution in the genesis of functionally divergent tumor territories.

OCM Member
Tufts University , USA
Biography :

Guo-fu Hu, PhD, is currently a Professor of Medicine, Tufts University School of Medicine, and an Investigator at Tufts Medical Center. He received his PhD from Shanghai Institute of Biochemistry, Chinese Academy of Sciences, and did his postdoctoral training in Beret L. Vallee lab located at the Center for Biochemical and Biophysical Sciences and Medicine, Harvard Medical School. He established his research program first in the Department of Radiology, Brigham and Women’s Hospital, and then in the Department of Pathology, Harvard Medical School, where he raised to the rank of Associate Professor of Pathology. He moved to Tufts Medical Center in 2010.

Research Interest :

Dr. Hu has been studying the mechanism and function of angiogenin in cancer and in angiogenesis for many years. His current focus is on the role of angiogenin and its receptor in regulating self-renewal and quiescence of stem cells, including hematopoietic stem cells and cancer stem cells.

OCM Member
The Ohio State University , USA
Biography :

Dr. Qien Wang is an Associatet Professor in the Department of Radiology and Comprehensive Cancer Center at the Ohio State University. Dr. Wang received his Bachelor Degree in Preventive Medicine in Shanxi Medical College in 1992, and obtained his PhD from Beijing Medical University in 1997 in China. Then, Dr. Wang worked as a Lecturer and Associate Professor at Peking University Medical Center for 4 years. During this time, his research was focused on understanding how gene and environmental exposure interact in carcinogenesis. In 2001, Dr. Wang joined Dr. Altaf Wani’s laboratory at the Ohio State University in the United States of America to study the mechanism of DNA repair as a Research Associate and Research Scientist. Since 2011, Dr. Wang has become a Tenure-track Assistant Professor at the Ohio State University, and was promoted to Associate Professor with Tenure in 2017.

Research Interest :

Dr. Wang’s research is focused on a mechanistic understanding of cancer progression, metastasis and recurrence, particularly in term of cancer stem cells.

OCM Member
Stony Brook University , USA
Biography :

Dr. Jingfang Ju is the Professor in the Department of Pathology at Stony Brook Medicine/Stony Brook University. Dr. Ju received his BS degree from the Northeastern University and Ph.D. in molecular biology and biochemistry at the University of Southern California. He completed his post-doctoral research fellowship at Yale Cancer Center, Yale University. Previously Dr. Ju has served as the Senior Scientist and Team Leader of high throughput genomics at a biopharmaceutical company, CuraGen Corporation in Connecticut.

Research Interest :

Dr. Ju's major research interest is in the development of miRNA based therapeutics and biomarker in gastrointestinal cancer. The Ju laboratory studies the mechanisms of microRNAs in cancer stem cell resistance, epithelial to mesenchymal transition (EMT), autophagy, and apoptosis. His group made initial discovery of the regulatory relationship between p53 tumor suppressor and microRNA. Dr. Ju and his group discovered the superior stability of microRNA in archival formalin fixed paraffin embedded (FFPE) clinical specimens which serves as the foundation of microRNA based biomarker discovery.

OCM Member
Université Pierre et Marie Curie , France
Biography :

Hervé Chneiweiss, first trained as a neurologist (movement disorders, Parkinson), HC was involved in the neurogenetics of human diseases such as cerebellar ataxias. For the last 15 years his scientific work was dedicated to the biology of astrocytes and their roles in brain tumor progression. He created in 2006 the Inserm laboratory U752, which gathered scientists and clinicians devoted to the study of brain tumors. HC is since 2014 director of the laboratory Neuroscience Paris Seine.

Research Interest :

Hervé Chneiweiss is studying molecular mechanisms involved in glial plasticity and underlying brain tumor development. Privileged technical expertise includes proteomics and cell cultures. Hervé Chneiweiss is also involved in bioethics and editor of Medecine/Sciences

OCM Member
Trinity College Dublin , Ireland
Biography :

After graduating from the Royal College of Surgeons in Ireland in 2004 with a PhD in Oncology, Stephen Maher spent 3 years as a visiting fellow at the National Cancer Institute in the US. In 2007 he returned to Ireland and Trinity College Dublin, St. James’s Hospital as a research fellow. In 2010 he established his own research group having secured an Irish Cancer Society Fellowship and a number of Health Research Board grants, predominantly in the area of radiation resistance in the treatment of gastrointestinal malignancy. In 2012 Stephen moved to the University of Hull and Hull York Medical School as a senior lecturer, where he led the Cancer Biology and Therapeutics lab. In 2016 Stephen returned to Trinity College Dublin as the James Ussher Assistant Professor in Translational Oncology, where he has set up new cancer radiobiology and hypoxia research cores.

Research Interest :

At the Department of Surgery, based at TCD and St. James’s Hospital Dublin, Stephen is primarily interested in understanding the complex molecular mechanisms underpinning resistance to radiotherapy and chemotherapy in oesophageal adenocarcinoma and malignant pleural mesothelioma. He is currently examining the role of microRNAs and cancer stems cells in driving resistance to treatment, and researching microRNA replacement therapy as a novel therapeutic to augment patient responses to conventional cytotoxics.

OCM Member
University of South Florida , USA
Biography :

Dr. Subhra Mohapatra has completed her PhD from University of Manitoba, Canada and postdoctoral studies at H. Lee Moffitt Cancer Center. Currently, she is an Associate Professor of Molecular Medicine in the Morsani College of Medicine, University of South Florida. During last 10 years, she has trained 13 postdocs and 16 graduate students involved in multidisciplinary research, such as biology, immunology, nanoscience and nanotechnology fields. She has authored over 62 scientific papers and holds 12 US patents. Her research is funded by the National Institute of Health, Veterans Administration and Florida Department of Health. She has been serving as an Academic Editor for the Plos One.

Research Interest :

Our research is focused on understanding the role of stromal cells in the tumor microenvironment that play a critical role in tumor growth and recurrence. We use nanotechnology–integrated cellular and molecular approaches to dissect major signaling pathways in cancers and identify novel drug targets and biomarkers and experimental therapeutics for cancer. We have also synthesized 3D/4D polymeric nano/micro scaffolds for studying tumor-stroma interactions in modulating cancer stem cell expansion and anticancer drug targets. We are also investigating the mechanism of anti-inflammatory triggers for traumatic brain injury.

OCM Member
University of New South Wales , Australia
Biography :

A/Prof Yong Li obtained his PhD degree at University of New South Wales (UNSW) Sudney, Australia in 2000. He became Cancer Research Group leader in 2006, and is an established cancer researcher, with expertise in cancer biomarker discovery, radiation biology, target cancer therapy and cancer metastasis. He was awarded an NHMRC Career Development Fellowship (Level 2) in 2010-2014; and an NHMRC Achievement Award (ranked No.1 in the industry fellow) in 2011. He was promoted to an Associate Professor in the Faculty of Medicine, UNSW since 2011, and a Principal Scientific Officer by the South Eastern Sydney Local Health District (SESLHD) since 2012. A/Prof Li has more than 100 career publications in cancer research area since 1999.

Research Interest :

Associate Professor Li’s research is aimed at a): To investigate novel biomarkers from human body fluids and tissues, cancer cell lines and animal models for cancer diagnosis and monitoring cancer progression; b): To investigate the mechanisms of cancer metastasis and chemo-/radio-resistance; c): To use targeted cancer therapy and combination therapy to control metastatic and therapeutic resistant cancers.

OCM Member
University of Cambridge , United Kingdom
Biography :

Joo-Hyeon Lee was fascinated by stem cell research through Ph.D. studies under the supervision of Prof. Daesik Lim in KAIST, Korea. She then joined Prof. Carla Kim’s laboratory at Harvard Medical School where she became interested in the study of adult lung stem cells. She established her own research group at the Cambridge Stem Cell Institute in 2016 and focuses on understanding cellular behavior and regulatory networks of adult stem and niche cells. Joo-Hyeon is currently Faculty member at the Department of Physiology, Development, and Neuroscience, University of Cambridge and was recently awarded the Royal Society and Wellcome Trust Sir Henry Dale Fellowship and ERC starting grant.

Research Interest :

Lee lab applies mouse genetics, ex vivo organoid co-cultures, live imaging, single-cell molecular analysis and mathematic modelling to define the identity and heterogeneity of diverse epithelial progenitor and mesenchymal populations, understand the key stem-mesenchymal interactions and the precise mechanisms that maintain tissue homeostasis and regeneration. Specifically, they are asking how the quiescent state is maintained and becomes activated, how cell fate is determined, and how niches develop and remodel in lung homeostasis, injury repair and early tumorigenesis.

OCM Member
Marseille Cancer Research Centre , France
Biography :

Claire Acquaviva obtained her PhD at Montpellier University working on the proteolytic regulation of Fos transcription factors in Dr. Marc Piechaczyk’s laboratory at the Institute of Molecular Genetics of Montpellier (IGMM). She worked as a post-doc in Jonathon Pines’ laboratory at the Gurdon Institute in Cambridge (UK) on the regulation of the cell cycle by proteolysis. She returned to France in Marseille to work on the centrosome, primary cilia, cell cycle regulation and associated pathologies in Dr. Daniel Birnbaum’s laboratory at the CRCM.

Research Interest :

Dr. Claire Acquaviva and Dr. Emilie Mamessier co-lead a group at the CRCM interested on Circulating Tumor Cells (CTCs) and their contribution to cancer metastases. Their main research interest is focused on breast and colon cancers and aim at better defining CTCs at high risk of seeding metastases. For this, they are combining innovative technologies (single cells isolation, microfluidic …) with complex organoids generation, either as a source (tumoroid) or a receptacle (multicellular organoid) for CTCs.

OCM Member
MedImmune , USA
Biography :

Dr. Elaine Hurt received her PhD in Biochemistry, Molecular Biology and Biophysics from the University of Minnesota in 1999 where she studied estrogen receptor signaling cascades. Dr. Hurt did her post-doctoral studies at the National Institutes of Health in the laboratory of Dr. Louis Staudt elucidating the molecular mechanisms governing therapeutic responses in lymphoma and multiple myeloma patients. In 2010, Dr. Hurt joined MedImmune to lead their cancer stem cell group. Prior to joining MedImmune, Dr. Hurt was a Staff Scientist at the National Cancer Institute, where she focused primarily on identifying and targeting prostate cancer stem cells. In 2014, Dr. Hurt became Adjunct Associate Professor in the Department of Biochemistry and Molecular Biology at the University of Maryland. She is the co-inventor on several patents, has been an invited speaker at numerous conferences, and has published over 50 scientific articles.

Research Interest :

Dr. Hurt’s research is aimed at developing novel therapeutics to treat cancer. In particular, she is focused on understanding and developing targets against cancer stem cells. In recent years, there is a focus on understanding how cancer stem cells shape and interact with the immune cells of tumor microenvironment.

OCM Member
Definiens , Germany
Biography :

Dr. Ralf Huss joined Definiens in 2013 and has more than 20 years of training and experience in histopathology and cancer research. Dr. Huss also co-founded the biotech company APCETH. He has published more than 100 papers, and has worked with the Nobel Laureates Rolf Zinkernagel and E. Donnell Thomas.

Research Interest :

He has training and experience in immunology, transplantation biology and stem cell research and also involved in identifying new tissue biomarkers to stratify cancer patients.

OCM Member
West China Hospital of Sichuan University , China
Biography :

Dr. Xianming Mo is a professor of internal medicine and acts as Director of Laboratory of Stem Cell Biology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University. He obtained his medicine degree from North Sichuan Medical College. Then he was trained in pathology and accept Master of Medicine in West China University of Medical Science. After obtaining a PhD degree in Peking Union Medical College, He moved to Humboldt-Universität zu Berlin and then to Medical College of Georgia as postdoctoral fellows. Then, he became junior faculty in Medical College of Georgia and senior scientist in Max Delbruck Center for Molecular Medicine. In 2006, he returned back to West China Hospital.

Research Interest :

Xianming Mo is interested in understanding the biology of physiological and pathological tissue stem cells including hematopoietic stem cell, neural stem cell and epithelial stem cells. Now one of his works focuses on the biology of the cancer stem cells, the constitution of cancer tissues in human patients with carcinoma and the their therapeutic implications in cancer.

OCM Member
Institut Paoli-Calmettes , France
Biography :

Emmanuelle Charafe-Jauffret is a doctor of medicine and a specialist in breast cancer, and is known for her expertise in cancer stem cells.

Research Interest :

She led a group on the characterization of cancer stem cells in the gland breast.

OCM Member
Student Ambassador
The Francis Crick Institute , United Kingdom
Biography :

Laurie J. Gay earned her Ph.D. at The Scripps Research Institute in La Jolla, California as a NIH Clinical and Translational Science Award Scholar. During this time, her research focused on the creation of metastasis models for understanding systemic and host influences on distant tumor development, especially brain metastasis. In 2013, she joined the laboratory of Dr. Ilaria Malanchi in her current position of Cancer Research UK Postdoctoral Fellow at the London Research Institute (now part of the Francis Crick Institute) in London.

Research Interest :

Laurie J. Gay is a cancer biologist with 11 years of pre-clinical research experience in oncology, with a focus on molecular mechanisms of tumor progression and metastasis.

OCM Member
Marseille Cancer Research Centre , France
Biography :

Emilie Mamessier performed her Ph.D. at Aix-Marseille University, followed by a postdoc at the Institute for Child health Research in Perth (Pr. P Holt, Australia) working on deregulated immune responses in asthma. Ten years ago, she switched to study cancer development, notably with the characterization of early stages of cancer, both at the tumor cell level and in relation to tumor microenvironment composition (CRCM and Center of Immunology Marseille Luminy CIML, Marseille).

Research Interest :

Emilie Mamessier research interest is focused on breast and colon cancers and aim at better defining CTCs at high risk of seeding metastases. For this, they are combining innovative technologies (single cells isolation, microfluidic …) with complex organoids generation, either as a source (tumoroid) or a receptacle (multicellular organoid) for CTCs.

Mail us at

Program enquiry
cancerstemcells@alliedconferences.org
Sponsors/Exhibiting/Advertising
cancerstemcells@alliedmeetings.org
General Queries
cancerstemcells@alliedmeetings.org
More details about sponsorship:sponsors@alliedacademies.com

Terms and Conditions

Responsibility

Delegates are personally responsible for their belongings at the venue. The Organizers will not be held responsible for any stolen or missing items belonging to Delegates, Speakers or Attendees; due to any reason whatsoever.

Insurance

Registration fees do not include insurance of any kind.

Transportation

Please note that any (or) all transportation and parking is the responsibility of the registrant.

Press/Media

Press permission must be obtained from Allied Academies Conference Organizing Committee prior to the event. The press will not quote speakers or delegates unless they have obtained their approval in writing. The Allied Academies is an objective third-party nonprofit organization. This conference is not associated with any commercial meeting company.

Requesting an Invitation Letter

For security purposes, letter of invitation will be sent only to those individuals who had registered for the conference. Once your registration is complete, please contact cancerstemcells@alliedconferences.org to request a personalized letter of invitation.

Regarding refunds, all bank charges will be for the registrant's account.

All cancellations or modifications of registration must be made in writing to contact@alliedacademies.com

Cancellation Policy

If Allied Academies cancels this event for any reason, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied Academies event which must occur within one year from the date of cancellation.

Postponement

If Allied Academies postpones an event for any reason and you are unable or unwilling to attend on rescheduled dates, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied Academies event which must occur within one year from the date of postponement.

Transfer of registration

All fully paid registrations are transferable to other persons from the same organization if registered person is unable to attend the event. Transfers must be made by the registered person in writing to contact@alliedacademies.com . Details must be included the full name of replacement person, their title, contact phone number and email address. All other registration details will be assigned to the new person unless otherwise specified.

Registration can be transferred to one conference to another conference of Allied Academies if the person is unable to attend one of the conferences.

However, Registration cannot be transferred if it is intimated within 14 days of the respective conference.

The transferred registrations will not be eligible for Refund.

Visa Information

Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible.

Allied Academies will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only.

Important note for failed visa applications: Visa issues cannot come under the consideration of cancellation policy of Allied Academies, including the inability to obtain a visa.

Refund Policy:

If the registrant is unable to attend and is not in a position to transfer his/her participation to another person or event, then the following refund arrangements apply:

Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overheads, we had to keep Refund Policy is as following slabs-

  • Before 60 days of the conference: Eligible for Full Refund less $100 service Fee
  • Within 60-30 days of Conference: Eligible for 50% of payment Refund
  • Within 30 days of Conference: Not eligible for Refund
  • E-Poster Payments will not be refunded.

Accommodation Cancellation Policy:

Accommodation Providers (Hotels) have their own cancellation policies, and they generally apply when cancellations are made less than 30 days prior to arrival. Please contact us as soon as possible, if you wish to cancel or amend your accommodation. Allied Academies will advise the cancellation policy of your accommodation provider, prior to canceling or amending your booking, to ensure you are fully aware of any non-refundable deposits.

Authorization Policy


Copyright © 2017-2018 Allied Academies, All Rights Reserved.